Canon U.S.A. and Liquent Announce High-Volume Printing Solutions for the Pharmaceutical Industry
Monday September 22, 11:44 am ET
LAKE SUCCESS, N.Y. & FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Sept. 22, 2003--
Liquent CoreDossier Now Supports Canon's Market Share Leading imageRUNNER Devices
In responding to the needs of pharmaceutical companies to affordably assemble and print complex regulatory, and mission critical documents, Canon U.S.A., Inc., an industry leader in networked imaging solutions, and Liquent, Inc., the global leader in regulatory publishing, intelligence, and intellectual property solutions, today announced Liquent's flagship CoreDossier product support for Canon's imageRUNNER line of high-volume printing devices.
ADVERTISEMENT
Using CoreDossier Version 5.5.3, pharmaceutical and life science companies can now efficiently manage the process of submitting large technical documents in accordance with strict U.S., European, and Japanese requirements by printing them on Canon imageRUNNER 7200, 8500, 85, 105, 110, and Pro 150+ models. CoreDossier, in use at nearly 300 locations around the world, enables life sciences companies to assemble and organize large volumes of documents into compliant formats and then creates the appropriate output in both PDF and Postscript formats. Publications - or dossiers - created with Liquent's products are often submitted to government agencies and include New Drug Applications, Common Technical Documents, Marketing Authorization Applications, and other reports.
As the U.S. market share leader in digital copier-based multifunction devices(1), Canon's imageRUNNER line now offers capabilities suited to address industry specific applications, in addition to those required by general office environments, with high-end document processing such as hole punching, tab insertion, and booklet-making, among others. The combination of this printing functionality and price point sets a new value proposition standard for the mid-to-large size pharmaceutical firm.
"Canon is very pleased to announce with Liquent a new, affordable printing solution for the pharmaceutical and life sciences industries," said Dennis Amorosano, Director and Assistant General Manager of Canon U.S.A. Integrated Business Systems Division. "Customers in these markets previously had limitations with respect to print devices. Our alliance with Liquent significantly expands their choices today, as the CoreDossier and imageRUNNER combo offers considerable cost and efficiency advantages that were previously unavailable."
"By collaborating with a premier printing supplier like Canon, Liquent adds even more value to our technology by increasing the availability of reliable, high-speed output," said Jim Nichols, Vice President of Product Management and Marketing at Liquent, Inc. "Liquent clients have completed thousands of regulatory submissions using Liquent technology and services. Our clients need cost-effective printing solutions to support their operational and regulatory environments. By working with Canon, Liquent is providing additional output options for our customers, ensuring that they can most effectively address their publishing requirements."
When printing documents, CoreDossier compiles documents into volumes and can create PostScript files embedded with commands specific to the selected imageRUNNER print device. The commands contain information such as where to place tabs, slip-sheets, or other high-end document finishing capabilities provided by imageRUNNER devices. These volumes are often 350 pages in length and may number as many as 1400 per submission, which are easily handled by the line of imageRUNNER's 72 to 150 page-per-minute speeds. Often multiple copies of the submission must be printed for dispatch and archival purposes.
CoreDossier 5.5.3 support for Canon imageRUNNER 7200, 8500, 85, 105, 110, and Pro 150+ devices is available today through Liquent, Inc.
Original Post